AU1453600A - Solid oral dosage forms containing alginic acid and famotidine - Google Patents

Solid oral dosage forms containing alginic acid and famotidine

Info

Publication number
AU1453600A
AU1453600A AU14536/00A AU1453600A AU1453600A AU 1453600 A AU1453600 A AU 1453600A AU 14536/00 A AU14536/00 A AU 14536/00A AU 1453600 A AU1453600 A AU 1453600A AU 1453600 A AU1453600 A AU 1453600A
Authority
AU
Australia
Prior art keywords
famotidine
dosage forms
alginic acid
oral dosage
solid oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14536/00A
Inventor
Edward J. Roche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Publication of AU1453600A publication Critical patent/AU1453600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
AU14536/00A 1998-11-04 1999-11-03 Solid oral dosage forms containing alginic acid and famotidine Abandoned AU1453600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10704598P 1998-11-04 1998-11-04
US06107045 1998-11-04
PCT/US1999/025250 WO2000025754A2 (en) 1998-11-04 1999-11-03 Solid oral dosage forms containing alginic acid and famotidine

Publications (1)

Publication Number Publication Date
AU1453600A true AU1453600A (en) 2000-05-22

Family

ID=22314559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14536/00A Abandoned AU1453600A (en) 1998-11-04 1999-11-03 Solid oral dosage forms containing alginic acid and famotidine

Country Status (2)

Country Link
AU (1) AU1453600A (en)
WO (1) WO2000025754A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0974366T3 (en) 1997-03-28 2007-01-29 Eisai Co Ltd Oral pharmaceutical preparations with reduced bitterness by masking
US7727548B2 (en) 2000-03-01 2010-06-01 Eisai R&D Management Co., Ltd. Rapidly disintegrable tablet containing polyvinyl alcohol
US6623785B2 (en) 2001-06-07 2003-09-23 Hewlett-Packard Development Company, L.P. Pharmaceutical dispensing apparatus and method
WO2005065639A2 (en) * 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
JO3112B1 (en) 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
TWI498132B (en) 2010-03-29 2015-09-01 Ferring Bv A fast dissolving pharmaceutical composition
AU2012307530B2 (en) 2011-09-16 2016-12-08 Ferring B.V. A fast dissolving pharmaceutical composition
WO2017091166A1 (en) * 2015-11-26 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Stable pharmaceutical compositions and process for their preparation
BR112023019653A2 (en) * 2021-03-24 2023-10-31 Johnson & Johnson Consumer Inc COATED FAMOTIDINE PARTICLE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
AU7218294A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations
WO1995001795A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate-antacid combinations
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
WO2000025754A2 (en) 2000-05-11
WO2000025754A3 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
AU7375598A (en) Stable oral pharmaceutical dosage forms
GB9613470D0 (en) Small solid oral dosage form
AU3977099A (en) Controlled release oral dosage form
AU2317699A (en) Dental restoratives
HUP0202338A2 (en) Pharmaceutical composition containing fenofibrate and preparation method
AP2000001757A0 (en) Solid oral dosage form comprising a combination of metforming and glibenclamide
AU5230399A (en) Pharmaceutical compositions and methods for managing scalp conditions
AU2638297A (en) Oral pharmaceutical preparation containing ibandronat
HK1039480A1 (en) Phenoxyacetic acid derivatives and medicinal compositions containing the same
AU4143999A (en) Oral composition comprising capsules
AU5565099A (en) Pharmaceutical compositions and methods for use
AU2543399A (en) Anticonvulsant drugs and pharmaceutical compositions thereof
AU1453600A (en) Solid oral dosage forms containing alginic acid and famotidine
HUP0100102A3 (en) Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
AU6213699A (en) Nutritional and pharmaceutical compositions
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
AUPP672198A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU6593100A (en) Interdental brush and interdental brush set
AU768217C (en) 2-methylpropionic acid derivatives and medicinal compositions containing the same
GB9817650D0 (en) Oral formulation
HUP0105446A3 (en) Pharmaceutical compositions comprising levosimendan and alginic acid
AU3538699A (en) Novel physiologically active substances
AU4384400A (en) Method and device for determining the color of teeth
AU2880699A (en) Pharmaceutical compositions and methods for use
HUP0102073A3 (en) Hydroxamic and carboxylic acid derivatives and medicaments containing them

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase